Saint Louis University

The United States of America, As Represented by the Secretary, Department of Health and Human Services

G.d. Searle & Company

Other

Monsanto Company

University System of Maryland

Galera Labs, LLC

Galera Therapeutics, LLC

Pharmacia Corporation

Metaphore Pharmaceuticals, Inc.

Daniela Salvemini

Kenneth Alan Jacobson

William L Neumann

Samuel J Tremont

Kishore Udipi

Amruta Reddy Poreddy

Dilip K Tosh

James A Sikorski

Dennis Patrick Riley

Yvette M Fobian

Margaret Lanahan Grapperhaus

Patrick J Lennon

Michael K Stern

Karl W Aston

Susan L Henke

Christopher Arnatt

Gina L C Yosten

Carrie L Kusturin

Kenneth A Jacobson

Simon Akerman

Marcela Romero-Reyes

Patrick Yeung, Jr

Willis K Samson

Disclosed herein are methods and compositions for the treatment and prevention of migraine, migraine-like headaches such as post-traumatic headache, and other related headaches by administering to a subject in need thereof a selective agonist for the human adenosine A3 receptor (A3AR) subtype.

Treatment of chronic headaches

Disclosed herein are compositions and methods for treating neuropathic pain in a subject in need thereof. Compositions disclosed herein are GPR183 antagonists. The methods include administering to a subject in need thereof a therapeutically effective amount of a GPR183 antagonist.

GPR183 antagonists for the treatment of pain

Disclosed herein are methods for treating neuropathic pain in a subject in need thereof. The methods include: administering to a subject in need thereof a therapeutically effective amount of an antagonist of P2Y14.

Treatment and prevention of neuropathic pain with P2Y14 antagonists

Disclosed are methods of diagnosing and treating endometriosis, and in particular, endometriosis-associated infertility.

Compositions and methods for diagnosing and treating endometriosis-related infertility

The disclosure provides methods and compositions for inhibiting pain by administering a GPR160 antagonist to a subject in need thereof. Also provided are methods of using GPR160 antagonists in combination with other pain therapies.

Methods of treating pain using anti-GPR160 antibodies

Disclosed are compounds of the formula (I) and (II): which are Aadenosine receptor agonists, pharmaceutical compositions comprising such compounds, and a method of use of these compounds, wherein X, Y, Z, R-R, and R-Rare as defined in the specification. These compounds are selective to the Areceptor, and are contemplated for use in the treatment or prevention of a number of diseases or conditions, for example, neuropathic pain.

A3 adenosine receptor agonists

Disclosed are compounds of the formula (I) and (II) which are Aadenosine receptor agonists, pharmaceutical compositions comprising such compounds, and a method of use of these compounds, wherein X, Y, Z, R-R, and R-Rare as defined in the specification. These compounds are selective to the Areceptor, and are contemplated for use in the treatment or prevention of a number of diseases or conditions, for example, neuropathic pain. 

Compounds and methods for utilizing compounds comprising a superoxide dismutase mimetic covalently linked to polyethylene glycol. Methods are also provided for preparing a superoxide dismutase mimetic covalently linked to a polyethylene glycol, the methods comprising reacting an activated polyethylene glycol with a superoxide dismutase mimetic, or alternatively, reacting a superoxide dismutase mimetic with an activated polyethylene glycol. A method is also provided for preventing or treating a disease or disorder in which superoxide anions are implicated, comprising administering to a subject in need thereof, a therapeutically effective amount of a compound comprising a superoxide dismutase mimetic covalently linked to a polyethylene glycol. Methods of determining the safety and efficacy of the compounds are also provided. Methods for determining the safety and efficacy can include methods in lab animals and humans.

Polyethylene glycolated superoxide dismutase mimetics

A method of treating neuropathic pain in a subject is provided. The method comprises administering to a subject a pharmaceutical composition comprising a therapeutically effective amount of an AAR agonist, optionally further including administering an analgesic.

[object Object]

The invention relates to methods for treating pain disorders including neuropathic and inflammatory pain and to methods to reduce or eliminate nociceptive tolerance induced by opiate analgesic use by administering an agent that suppresses or blocks S1P biological activity.

Methods of treating antinociceptive tolerance

Methods of treating pain

Compounds and methods for utilizing compounds comprising a superoxide dismutase mimetic covalently linked to polyethylene glycol. Methods are also provided for preparing a superoxide dismutase mimetic covalently linked to a polyethylene glycol, the methods comprising reacting an activated polyethylene glycol with a superoxide dismutase mimetic, or alternatively, reacting a superoxide dismutase mimetic with an activated polyethylene glycol. A method is also provided for preventing or treating a disease or disorder in which superoxide anions are implicated, comprising administering to a subject in need thereof, a therapeutically effective amount of a compound comprising a superoxide dismutase mimetic covalently linked to a polyethylene glycol. Methods of determining the safety and efficacy of the compounds ere also provided. Methods for determining the safety and efficacy can include methods in lab animals and humans.

Synthetic low molecular weight catalysts for the dismutation of superoxide are potent analgesics that are effective in elevating the pain threshold in hyperalgesic conditions such as arthritis, and also operate to prevent or reverse tolerance to opioid analgesics.

Analgesic methods using synthetic catalysts for the dismutation of superoxide radicals

The present invention provides a method for the treatment of diseases by the decomposition of peroxynitrite, preferably decomposition to benign products, comprising the use of a complex which is a selected ligand structure providing a complexed metal such as Mn, Fe, Ni and V transition metals. The method of use, as well as novel pharmaceutical compositions therefor, are for the treatment of diseases advantageously affected by decomposition of peroxynitrite ed at a rate over the natural background rate of decay of peroxynitrite in humans suffering from the disease which comprises administration of an amount of a complex, in dosage unit form, which is effective for such acceleration of the decomposition of peroxynitrite .

Methods of use for peroxynitrite decomposition catalysts, pharmaceutical compositions therefor

The present invention relates to compounds which are effective as catalysts for dismutating superoxide and, more particularly, the manganese or iron complexes of substituted, unsaturated heterocyclic pentaazacyclopentadecane ligands which catalytically dismutate superoxide.

Growing community of inventors

Chesterfield, MO, United States of America

Daniela Salvemini